Search

MasTec (MTZ) has its hand in growing areas and its chart looks bullish.

Protecting the principle that all Internet traffic should be treated equally.

Despite Apple stores being faked in China, the company’s business there is soaring.

Last Tuesday I asked how you feel about your taxes. Are they too high or too low? Are they fair? (You can read the whole issue here.) Many of you agreed with me that your taxes feel unfair, and you gave a variety of reasons. A reader named Bob Bottini...

A few investing mid-year resolutions that you can use to improve your investing performance in 2011 and beyond.

Small caps will outperform large caps in 2016. Given that small caps outperform over the long-term, yet have underperformed large caps for two consecutive years (2014 and 2015), and have fallen so much year-to-date, I see solid potential for small-cap outperformance over the next 12 months.

Since she was working at Abbott, Grace Groner bought three shares of the company’s stock for $60 a share.

WHAT TO DO NOW: Remain defensive, but be ready to take some action. From a top-down perspective, the market is improving, with our Cabot Tides on the verge of a green light. However, individual stocks remain a mine field, with many acting better but plenty of blowups, including many high-profile names, like Meta (META) today and our own Wolfspeed (WOLF), which collapsed today after earnings; we sold our shares earlier today via a special bulletin.

Monday after the close, sources close to the Senate banking committee said the panel will delay its vote on key cannabis banking reform known as the SAFE Banking Act. Some investors had expected the vote to happen next week. This update probably helps explain sector weakness Tuesday.

Mike Cintolo sits down for a Q&A session about where he thinks the market goes from here in the face of rising volatility and geopolitical pressures.

Gold and precious metals expert Clif Droke, chief analyst of Sector Xpress Gold & Metals Advisor, explains why you need to have exposure to gold in your portfolio.

Today’s recommendation is another company tapping into the explosive growth in genomic testing. It makes diagnostic tests, which pits it against larger rivals like Illumina (ILMN) and Gardant Health (GH). But this small company plays in three very specific markets where its next-gen products are emerging as market leaders. And new collaborations with the likes of Johnson and Johnson (JNJ) and Loxo Oncology, now part of Eli Lilly (LLY), are further evidence that it’s on the right path. All the details are inside. Enjoy, and Happy 4th of July!

Conventional investing wisdom says to keep tight stop losses on volatile stocks. But if you don’t loosen your stops, you could miss out on some big profits.

Cabot Market Letter recommended this LED marker that recently blasted off.

We get a lot of emails here at Cabot and one of the most frequently asked questions is, “Which Cabot letter is right for me?”

We at Cabot will manage our growth portfolios with our usual total disregard for the political campaigns.

These days I’m relatively bullish. Not only did the market snap back powerfully from its early-December retreat, but we saw a couple of “blast-off” indications—rare signs of power that almost always portend solid market returns during the next three to nine months.

In the short-term, we remain in the midst of a contraction of liquidity, as the reverberations from the collapse of the sub-prime credit markets continue. Eventually, these markets will stabilize, and when the smoke clears we’ll see a market that is smaller, cleaner and saner ... and liquidity will return. How long this will take I have no idea.

Monday’s column, sparked by news of the Amethyst Initiative, the proposal by 129 college presidents to discuss lowering the drinking age, brought some great responses. I’ve reprinted many below (edited to save you time), and I thank you all for reading and taking the time to respond.